Reshape Lifesciences Inc (OTCMKTS:RSLS) major shareholder Armistice Capital Master Fund acquired 200,000 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The stock was purchased at an average cost of $0.07 per share, for a total transaction of $14,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Armistice Capital Master Fund also recently made the following trade(s):
- On Thursday, August 8th, Armistice Capital Master Fund acquired 350,000 shares of Reshape Lifesciences stock. The stock was purchased at an average cost of $0.07 per share, for a total transaction of $24,500.00.
- On Friday, July 26th, Armistice Capital Master Fund acquired 500,000 shares of Reshape Lifesciences stock. The stock was purchased at an average cost of $0.08 per share, for a total transaction of $40,000.00.
OTCMKTS:RSLS traded down $0.00 during midday trading on Wednesday, hitting $0.07. The stock had a trading volume of 226,803 shares, compared to its average volume of 149,921. Reshape Lifesciences Inc has a one year low of $0.04 and a one year high of $10.64. The stock has a 50-day moving average of $0.12 and a 200 day moving average of $0.16. The company has a quick ratio of 0.93, a current ratio of 1.04 and a debt-to-equity ratio of 0.05.
Reshape Lifesciences (OTCMKTS:RSLS) last announced its quarterly earnings data on Wednesday, August 14th. The medical device company reported ($0.84) earnings per share (EPS) for the quarter. Reshape Lifesciences had a negative return on equity of 86.52% and a negative net margin of 689.90%. The firm had revenue of $4.45 million during the quarter.
Reshape Lifesciences Company Profile
ReShape Lifesciences Inc, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses.
Recommended Story: Cost of Equity
Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.